Using Dimethyl Fumarate to Treat Multiple Sclerosis

A patent detailing the specific daily dosage of 480mg of dimethyl fumarate for treating multiple sclerosis to protect nerve cells.

What it covers

This patent describes a specific treatment protocol for multiple sclerosis (MS) using dimethyl fumarate or monomethyl fumarate. The core mechanism involves administering a total of 480 mg per day, which the patent claims activates the Nrf2 cellular pathway. This pathway is responsible for protecting cells from oxidative stress, which helps reduce the damage to the protective coating of nerves (demyelination) and prevents nerve cell death. The patent specifies that this dose can be split into multiple equal administrations, such as two doses per day.

What it doesn't cover

• —Does not cover dosages significantly different from the 480 mg per day threshold.
• —Does not cover the use of dimethyl fumarate for diseases other than multiple sclerosis.
• —Does not cover non-oral delivery methods, such as intravenous or intramuscular injections.
• —Does not cover chemical formulations that include active ingredients beyond the specified fumarates and standard excipients.

The clever bit

The patent links the clinical efficacy of a specific 480 mg dose directly to the upregulation of NQO1, a biomarker for the Nrf2 pathway, providing a biological rationale for why this specific amount of the drug works to protect neurons.

Why it matters

This patent is central to the clinical use of Tecfidera, a major oral medication for MS. By establishing a specific, effective dosage regimen, it provided a clear path for regulatory approval and commercialization of a once-daily or twice-daily pill, which was a significant improvement over injectable MS therapies.

Real-world examples

• 1.Tecfidera (dimethyl fumarate)